What type of study is this?

This is a Literature Review study.

September 10, 2025Open Access

A Critical Review of Commercial Collagen-Based Scaffolds in Bone Regeneration: Functional Properties and Clinical Evidence from Infuse® Bone Graft

Key Points

Strong osteoinductive activity from rhBMP-2 promotes mesenchymal stem cell differentiation and enhances bone regeneration.
Preclinical and clinical studies confirm significant regeneration in craniofacial and orthopedic models, validating rhBMP-2 as a useful alternative to autologous grafts.
High costs associated with rhBMP-2 limit its accessibility, though some studies propose similar overall costs to autografts after considering reduced complications.
Innovations in scaffold design and delivery systems improve rhBMP-2 bioavailability, but safety concerns and mechanical limitations must be addressed.

Abstract

This review article provides a comprehensive evaluation of Infuse® and InductOs®, two ground-breaking recombinant human Bone Morphogenetic Protein-2 (rhBMP-2)-based bone graft products, focusing on their tissue-level regenerative responses, clinical applications, and associated costs. Preclinical and clinical studies demonstrate that rhBMP-2 induces strong osteoinductive activity, effectively promoting mesenchymal stem cell differentiation and vascularized bone remodeling. While generally well-tolerated, these osteoinductive effects are dose-dependent, and excessive dosing or off-label use may result in adverse outcomes, such as ectopic bone formation or soft tissue inflammation. Histological and imaging analyses in craniofacial, orthopedic, and spinal fusion models confirm significant bone regeneration, positioning rhBMP-2 as a viable alternative to autologous grafts. Notably, advances in delivery systems and scaffold design have enhanced the stability, bioavailability, and targeted release of rhBMP-2, leading to improved fusion rates and reduced healing times in selected patient populations. These innovations, alongside its proven regenerative efficacy, underscore its potential to expand treatment options in cases where autografts are limited or unsuitable. However, the high initial cost, primarily driven by rhBMP-2, remains a critical limitation. Although some studies suggest overall treatment costs might be comparable to autografts when factoring in reduced complications and operative time, autografts often remain more cost-effective. Infuse® has not substantially reduced the cost of bone regeneration and presents additional safety concerns due to the rapid (burst) release of growth factors and limited mechanical scaffold support. Despite representing a significant advancement in synthetic bone grafting, further innovation is essential to overcome limitations related to cost, mechanical properties, and controlled growth factor delivery.

Read Full Paperexternally

AI से पूछें

Bookmark

View Full Paper